Navigation Links
Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
Date:4/8/2009

INDIANAPOLIS, April 8 /PRNewswire-FirstCall/ -- Phase III data, published online this week in the Journal of Clinical Endocrinology & Metabolism, showed that arzoxifene, an investigational selective estrogen receptor modulator (SERM) being developed by Eli Lilly and Company (NYSE: LLY), significantly increased lumbar spine and total hip bone mineral density (BMD) in postmenopausal women with normal or low bone mass, versus placebo.

In addition, arzoxifene, dosed at 20 mg/day, decreased biochemical markers of bone turnover, and showed a neutral effect on the uterus and endometrium.

"It is encouraging that arzoxifene showed the potential of bone loss prevention, with significant gains in BMD in the spine and hip areas in postmenopausal women in this study," said lead investigator Michael Bolognese, M.D., Bethesda Health Research Center in Bethesda, Maryland. "I am pleased with the results from this study and believe that arzoxifene at 20 mg/day may be a therapeutic option worthy of continued development."

Arzoxifene is being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis or low bone mass.

These data are from the "FOUNDATION" Study, one of three Phase III trials for arzoxifene. In March, data from the second Phase III trial called "NEXT" study were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) annual meeting. The third Phase III trial, the "GENERATIONS" Study, is a five-year, randomized, double-blind, placebo-controlled study assessing the effects of arzoxifene on vertebral fracture incidence and on invasive breast cancer incidence in postmenopausal women with osteoporosis or with low bone density. Res
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma
5. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
6. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
7. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
10. Newly Approved HIV Drug Shows Great Promise
11. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... identified an important cancer gene that could lead to more ... a disease which currently has a poor prognosis. The ... was one of a number of significant genetic differences found ... are the most common brain tumour in children. Clinicians ...
... Up-to-Date ... , ... NJ (PRWEB) May 18, 2010 -- Projects In Knowledge ( www.projectsinknowledge.com ), a fully ... approved iPhone application developer. The company has just launched Living Medical Textbook Neurology: Multiple ...
... adds to ongoing health risks , TUESDAY, May ... of smoke, dust, fumes and gases among those involved ... Trade Center ultimately compromised the workers, sense of smell, ... diminished ability to detect odors and irritants, researchers at ...
... ... ... look like two ordinary guys, and they will even tell you that’s all they are, but ... after nearly 3 months of rollerblading across the United States. With such a grueling task, they ...
... ... the news because they are becoming more popular and may even be permanent alternatives to ... the results people want. Advancements in technology and techniques are also making these treatments ... ...
... ... played a role in the 30th Annual Texas History Day Contest; albeit, one behind the ... Irving, TX ... provider of upper extremity rehabilitation services recently played a role in the 30th Annual Texas ...
Cached Medicine News:Health News:Genetics of children's brain tumor unlocked 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 3Health News:Lost Sense of Smell Noted Among Ground Zero Workers Post-9/11 2Health News:Rollerbladers Finish Grueling Cross Country Trek Helped by Tahitian Noni Products 2Health News:Dr. Alexander Rivkin's Pioneering Non-Surgical Nose and Eye Transformations Are Making Headlines and May Be Permanent Solutions 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: